Orthostatic hypotension
"orthostatic hypotension"[MeSH Terms] AND management
orthostatic hypotension blood pressure postural change diagram

This physiological tracing panel illustrates cardiovascular and autonomic nervous system responses in a patient with orthostatic hypotension. Panel A shows continuous blood pressure (BP) recordings during postural transitions from lying to standing, highlighting rapid hypotension leading to presyncope and the compensatory effect of leg crossing (arrow in 'c'). Panel B displays a qualitatively normal hypertensive and tachycardic response to sustained handgrip. Panels C and D provide integrated microneurography recordings of muscle sympathetic nerve activity (MSNA, lower traces) alongside BP (upper traces). In Panel C (apnea test), a marked increase in MSNA precedes a rise in BP, with subsequent sympathetic inhibition during the post-apnea BP rebound. Panel D (Valsalva maneuver) demonstrates a similar pattern: initial sympathetic activation during the strain phase followed by profound inhibition during the phase IV BP overshoot. Panel E illustrates skin sympathetic nerve activity (SSNA) at rest, showing a characteristic arousal response (arrow). These findings help evaluate baroreceptor-governed sympathetic outflow and peripheral autonomic integrity in neurogenic orthostatic disorders.

This diagnostic composite shows physiological recordings from a healthy volunteer during head-up tilt testing, presented in two panels (A and B) with different time scales. Each panel displays synchronized waveforms for Heart Rate (HR), Blood Pressure (BP), Systolic Blood Pressure (BPs), Tilt angle, Respiration (Resp.), and Electrocardiogram (EKG). The primary educational focus is the identification of Mayer waves—low-frequency oscillations in blood pressure—and their relationship to respiration and orthostatic stress. Panel A features a blue rectangle highlighting that the BPs oscillations (Mayer waves) occur at a significantly lower frequency than the respiratory cycles, indicating they are not respiratory-driven. Following the upward tilt, the BPs maintains stability without the precipitous drop characteristic of orthostatic hypotension. The EKG and HR tracings provide context for cardiac autonomic response during the postural change. This visualization is used in cardiology and neurology to distinguish between normal autonomic blood pressure regulation and neurogenic orthostatic hypotension.

This diagnostic line graph displays a real-time beat-to-beat analysis of heart rate (HR) and systolic blood pressure (SBP) in a patient with COVID-19 and low baroreflex sensitivity. The data is divided into three clinical phases: 1. Rest (5 min), 2. Orthostatic hypotension (active standing), and 3. Head up tilt test. The upper panel shows the HR in beats per minute (bpm), showing an upward trend and increased variability from a baseline of ~95 bpm at rest to over 115 bpm during postural challenges. The lower panel displays SBP in mmHg, oscillating between 100 and 150 mmHg. A central line indicates mean SBP, while a surrounding shaded area represents the beat-to-beat variability or standard deviation. The visual demonstrates impaired autonomic nervous system (ANS) regulation, characterized by significant fluctuations in hemodynamic parameters during orthostatic stress. This educational tool illustrates the cardiovascular response to autonomic provocation in the context of post-viral dysautonomia.

Summary : This illustration summarizes key symptoms of autonomic dysfunction, highlighting orthostatic hypotension/intolerance to blood pressure medications, chronic gastrointestinal issues, and erectile dysfunction. illustration: # Title & Main Text : • Title: "Autonomic Dysfunction" (blue header). • Symptom 1: "Orthostatic hypotension/intolerance to blood pressure meds". • Symptom 2: "Chronic diarrhea/constipation/weight loss". • Symptom 3: "Erectile dysfunction". # Visual Elements : • Symptom 1: Cartoon of a person holding their head, surrounded by swirling lines indicating dizziness. • Symptom 2: Illustration of a person holding their abdomen, suggesting gastrointestinal discomfort. • Symptom 3: Diagram of male pelvic anatomy, highlighting erectile dysfunction. # Layout : • Vertical arrangement: Title at top, followed by three symptom sections, each with corresponding illustration and text. • Each symptom is paired with a circular icon-style illustration. # Analysis : • The figure visually organizes and emphasizes three major symptom domains of autonomic dysfunction: cardiovascular (orthostatic hypotension), gastrointestinal (chronic diarrhea/constipation/weight loss), and genitourinary (erectile dysfunction). • The use of distinct icons and clear text aids rapid recognition of symptom clusters associated with autonomic dysfunction.
| Age Group | Prevalence |
|---|---|
| <50 years | <5% |
| >70 years | up to 20% |

| Feature | Non-Neurogenic OH | Neurogenic OH (NOH) |
|---|---|---|
| HR increase on standing | >15 bpm (intact reflex) | <15 bpm (blunted) |
| ΔHR/ΔSBP ratio | >0.5 beats/min/mmHg | <0.5 beats/min/mmHg |
| Mechanism | Volume depletion, drugs, cardiac | Impaired NE release, autonomic failure |
| Prognosis | Better | Worse (44% mortality at 30 months; >60% at 10 years) |
| Class | Features |
|---|---|
| I | Asymptomatic; may have syncope/falls |
| II | Symptoms weekly/monthly; mild-moderate limitation |
| III | Frequent severe symptoms; markedly limit daily activity |
| IV | Daily severe symptoms; significant disability |
| Drug | Dose | Mechanism | Key Notes |
|---|---|---|---|
| Fludrocortisone | 0.1-0.2 mg/day (up to 0.4 mg/day) | Mineralocorticoid → expands plasma volume, mild α-agonist effect | First-line; monitor for supine HTN, hypokalemia, pedal edema, headache; check bone density long-term |
| Midodrine | Start 2.5 mg TID → up to 15 mg TID (most respond to 7.5-10 mg TID) | Selective α1-adrenoceptor agonist → arterial and venous constriction | Onset 30-60 min, duration 4 h; last dose before 6 PM; side effects: scalp tingling, goosebumps, urinary urgency |
| Droxidopa | 100 mg TID → 400-600 mg TID | NE precursor → converted to norepinephrine in sympathetic terminals and non-neuronal tissues | FDA-approved for NOH; improves symptoms and reduces falls in Parkinson's; supine HTN risk |
| Pyridostigmine | Start 30 mg TID → 60 mg TID | Cholinesterase inhibitor → enhances ganglionic transmission | Does not promote supine HTN (advantage); benefits patients with slow GI motility; side effects: cramps, diarrhea |
| Atomoxetine | 10-18 mg/morning | NE reuptake inhibitor (SNRI-like) | Adjuvant therapy; monitor for CNS stimulation (anxiety, tremor) |